Tamarack Advisers’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Tamarack Advisers’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,500,000	Closed	-$1.02M	–	42
2019 Q4	$1.02M	Sell	2,500,000 -2,000,000	-44%	-$3.32M	0.23%	25
2019 Q3	$9M	Buy	4,500,000 +1,150,000	+34%	+$2.33M	2.35%	14
2019 Q2	$7.44M	Buy	3,350,000 +950,000	+40%	+$2.43M	2.26%	16
2019 Q1	$7.58M	Buy	2,400,000 +275,000	+13%	+$890K	3.01%	12
2018 Q4	$5.29M	Buy	2,125,000 +65,000	+3%	+$216K	2.16%	15
2018 Q3	$8.28M	Buy	2,060,000 +60,000	+3%	+$265K	2.36%	17
2018 Q2	$7.56M	Buy	2,000,000 +125,000	+7%	+$326K	2.53%	14
2018 Q1	$4.35M	Hold	1,875,000	–	–	2.07%	15
2017 Q4	$2.91M	Buy	1,875,000 +125,000	+7%	+$201K	1.59%	21
2017 Q3	$3.73M	Sell	1,750,000 -50,000	-3%	-$170K	2.28%	15
2017 Q2	$8.14M	Sell	1,800,000 -25,000	-1%	-$90.7K	4.75%	9
2017 Q1	$5.49M	Hold	1,825,000	–	–	3.43%	15
2016 Q4	$5.04M	Sell	1,825,000 -375,000	-17%	-$1.07M	3.56%	13
2016 Q3	$6.94M	Buy	+2,200,000	New	+$8.02M	2.18%	16

Other funds holding CORV

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Tamarack Advisers's CORV Position: Q1 2020 in Review

Tamarack Advisers sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q1 2020, closing a stake of 2,500,000 shares — an estimated $1.02M sold.

Tamarack Advisers first reported a position in CORV in Q3 2016 and held it in 14 quarters. The position peaked at $9M in Q3 2019. 27 funds tracked by Wall St. Rank hold CORV as of Q1 2020.

Tamarack Advisers reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q1 2020 after selling out during the quarter.
Tamarack Advisers sold 2,500,000 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q1 2020, an estimated $1.02M.
Tamarack Advisers first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q3 2016 and held it in 14 quarters.
Tamarack Advisers's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $9M in Q3 2019.
27 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q1 2020.

Based on Tamarack Advisers's 13F filing for Q1 2020, filed 14 May 2020.